[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Endocrinology](https://durgical.com/en/endocrinology/) › [Endocrine tumours and inherited syndromes](https://durgical.com/en/endocrinology/areas/tumours-genetics/) › Neuroendocrine tumours: markers, grading and functional imaging

# Neuroendocrine tumours: markers, grading and functional imaging

- Diagnostic approach

Hormone-making tumours can hide for years in the gut, [pancreas](https://durgical.com/en/anatomy/pancreas/) or lung. What they make, how fast they grow and where they are guides every decision.

Updated Nov 16, 2026

**See it in 3D:** [Pancreas](https://durgical.com/en/anatomy/pancreas/) · [Duodenum](https://durgical.com/en/anatomy/duodenum/) · [Ileum](https://durgical.com/en/anatomy/ileum/) · [Liver](https://durgical.com/en/anatomy/liver/)

## Key points

- Functioning NET = hormone inappropriately high for the state it has caused.
- Ki-67: G1 below 3%, G2 3–20%, G3 above 20%; carcinoma = poorly differentiated.
- Somatostatin-receptor PET/CT stages and selects for receptor-targeted treatment.
- [Insulinoma](https://durgical.com/en/conditions/insulinoma/) mostly benign; [gastrinoma](https://durgical.com/en/conditions/zollinger-ellison-syndrome/), glucagonoma, VIPoma and somatostatinoma mostly malignant.
- Gastrinoma: high gastrin with an acid [stomach](https://durgical.com/en/anatomy/stomach/); think MEN1.
- Chromogranin A rises falsely with proton-pump inhibitors.

On this page

- The basics Key points
- What it is
- How to think about it
- What to know
- Step-by-step approach
- The functional pancreatic and duodenal NETs side by side
- Common traps
- Elsewhere in DurgiPedia

- Clinical Keys to the differential

- Treatment Next step / Initial management

- Study Test yourself

- Connections Connections

## What it is

Neuroendocrine tumours (NETs) arise from the hormone-making cells scattered through the gut, pancreas and lung, and less often the [thymus](https://durgical.com/en/anatomy/thymus/) and other sites. The small intestine, [rectum](https://durgical.com/en/anatomy/rectum/), [appendix](https://durgical.com/en/anatomy/vermiform-appendix/), stomach, pancreas and bronchi are the usual primaries. Functioning NETs secrete a hormone that causes a syndrome ([serotonin](https://durgical.com/en/biochemistry/molecules/serotonin/), insulin, gastrin, [glucagon](https://durgical.com/en/pharmacology/glucagon/), VIP, somatostatin, ACTH); most pancreatic and many gut NETs are non-functioning and present with mass effect, [liver](https://durgical.com/en/anatomy/liver/) metastases or as an incidental finding. Pathology confirms neuroendocrine nature (synaptophysin, chromogranin A staining) and separates well-differentiated NETs, graded G1 to G3 by Ki-67 index and mitotic count (WHO), from poorly differentiated neuroendocrine carcinomas (small-cell or large-cell type), which behave like aggressive cancers.

## How to think about it

A normal endocrine cell is part of a loop: it secretes until the result arrives, then the brake goes on ([glucose](https://durgical.com/en/biochemistry/molecules/glucose/) falls, insulin stops). A functioning NET has lost its brake and keeps secreting whatever the result, so the diagnosis is always a hormone that is inappropriately high for the state it has created: insulin high while glucose is low, gastrin high while the stomach is full of acid. Then ask three questions of every NET: what does it make (hormones and markers), how fast is it (differentiation and Ki-67), and where is it, carrying which receptor (somatostatin-receptor imaging, which also says whether receptor-targeted treatment can work).

## What to know

- Functional diagnosis pairs the hormone with the state it should be suppressed in: insulin with low glucose, gastrin with gastric pH, [5-HIAA](https://durgical.com/en/endocrinology/carcinoid-syndrome-flushing-diarrhoea-and-5-hiaa/) for serotonin.
- Chromogranin A is a general NET marker for follow-up, not a screening test: proton-pump inhibitors, atrophic gastritis, kidney failure and [heart failure](https://durgical.com/en/conditions/heart-failure/) raise it falsely.
- WHO grading of well-differentiated gastroenteropancreatic NETs: G1 Ki-67 below 3%, G2 3–20%, G3 above 20%; poorly differentiated neuroendocrine carcinoma is a separate, more aggressive entity.
- Somatostatin-receptor PET/CT (gallium-68 or [copper](https://durgical.com/en/biochemistry/topics/copper/) -64 DOTATATE) is the most sensitive staging scan for well-differentiated NETs and selects patients for [somatostatin analogues](https://durgical.com/en/pharmacology/classes/somatostatin-analogues/) and peptide receptor radionuclide therapy.
- Poorly differentiated carcinomas and many insulinomas carry few somatostatin receptors: FDG PET suits the carcinomas; endoscopic ultrasound or [GLP-1](https://durgical.com/en/physiology/appetite-hormones-leptin-ghrelin-and-incretins/) receptor imaging help find insulinomas.
- About a quarter of gastrinomas, and many pancreatic NETs in young patients, are part of MEN1.
- Small-intestinal NETs are often found late, with liver metastases, mesenteric fibrosis or bowel obstruction.

## Step-by-step approach

- Suspect a NET from a hormone syndrome, an unexplained liver or pancreatic mass, or an incidental finding at endoscopy or imaging.
- If there is a syndrome, prove the hormone excess first: measure the [matching](https://durgical.com/en/epidemiology/matching/) hormone in the state in which it should be suppressed.
- Confirm on tissue: synaptophysin and chromogranin A staining, differentiation, Ki-67 index and mitotic count.
- Stage with multiphase CT or liver MRI and somatostatin-receptor PET/CT; add FDG PET for high-grade tumours.
- Look for MEN1 or another inherited syndrome when the patient is young, tumours are multiple or calcium is high.
- Control the hormone before procedures: a somatostatin analogue for most; [diazoxide](https://durgical.com/en/pharmacology/diazoxide/) and frequent meals for insulinoma.
- Plan in a NET team: surgery for localised disease; somatostatin analogues, radionuclide therapy, targeted drugs or chemotherapy when advanced.

## The functional pancreatic and duodenal NETs side by side

| Tumour | Hormone | Telltale picture | Key test | Site and behaviour |
| --- | --- | --- | --- | --- |
| Insulinoma | Insulin | [Hypoglycaemia](https://durgical.com/en/conditions/hypoglycaemia/) when fasting or exercising, relieved by eating (Whipple triad); weight gain | Supervised fast: low glucose with inappropriately high insulin, C-peptide and proinsulin | Anywhere in the pancreas, usually single and small; about 90% benign |
| Gastrinoma (Zollinger–Ellison) | Gastrin | Multiple or refractory ulcers, ulcers beyond the duodenal bulb, diarrhoea | High fasting gastrin with acid gastric pH; secretin test when unclear | [Duodenum](https://durgical.com/en/anatomy/duodenum/) more than pancreatic head (gastrinoma triangle); mostly malignant |
| Glucagonoma | Glucagon | Necrolytic migratory erythema, diabetes, weight loss, venous thrombosis | High glucagon | Body and tail; mostly malignant |
| VIPoma | VIP | Large-volume watery diarrhoea that continues while fasting, [low potassium](https://durgical.com/en/conditions/hypokalaemia/), low gastric acid | High VIP during the diarrhoea | Body and tail; mostly malignant |
| Somatostatinoma | Somatostatin | Diabetes, [gallstones](https://durgical.com/en/conditions/gallstones/) and fatty stools: everything switched off | High somatostatin; often found as a mass | Pancreatic head or duodenum (duodenal ones linked to NF1); mostly malignant |
| Non-functioning NET | None that causes symptoms | Mass effect, jaundice, liver metastases or an incidental finding | Tissue diagnosis and staging | The commonest pancreatic NET; behaviour set by size and grade |

## Keys to the differential

- Diarrhoea has many NET causes: serotonin, VIP (fasting does not stop it), gastrin (acid inactivates [pancreatic lipase](https://durgical.com/en/biochemistry/topics/lipase-as-a-lab-test/)), somatostatin (fat malabsorption) and somatostatin analogue treatment itself.
- A NET found at colonoscopy or appendicectomy is sized and graded before deciding on more surgery; small rectal and appendiceal NETs are usually cured by removal.
- Somatostatin analogues improve most hormone syndromes but can worsen hypoglycaemia in some insulinomas, because they also suppress glucagon and [growth hormone](https://durgical.com/en/pharmacology/classes/growth-hormone/).
- Poorly differentiated neuroendocrine carcinoma behaves like small-cell [lung cancer](https://durgical.com/en/conditions/lung-cancer/) and is treated with chemotherapy, not as a slow NET.

## Next step / Initial management

- The hormone that fits the syndrome (insulin with glucose, gastrin with gastric pH, glucagon, VIP, urine or plasma 5-HIAA), with chromogranin A as a follow-up marker.
- Biopsy for differentiation and Ki-67; stage with multiphase CT or liver MRI and somatostatin-receptor PET/CT.
- Control symptoms while staging: somatostatin analogue; proton-pump inhibitor for gastrinoma; diazoxide and frequent meals for insulinoma.
- Calcium, PTH and prolactin when MEN1 is possible, and [genetic testing](https://durgical.com/en/biochemistry/topics/genetic-tests-what-each-one-finds/) if they are abnormal or the patient is young.
- Refer every suspected or confirmed NET to a multidisciplinary neuroendocrine tumour team (endocrinology, surgery, oncology, nuclear medicine).

## Common traps

- **A high chromogranin A proves a NET**: proton-pump inhibitors, atrophic gastritis and kidney failure raise it, so it is a follow-up marker, not a diagnostic test.
- **A high gastrin means a gastrinoma**: the commonest causes are acid-suppressing drugs and atrophic gastritis, where gastrin is high because acid is low; gastrinoma is high gastrin with an acid stomach.
- **A grade 3 NET is the same as a neuroendocrine carcinoma**: G3 NETs are well differentiated and often slower, while poorly differentiated carcinomas need platinum-based chemotherapy.
- **A negative somatostatin-receptor scan rules out a NET**: many insulinomas and high-grade carcinomas lack the receptor, so they need endoscopic ultrasound, GLP-1 receptor imaging or FDG PET.
- **Every pancreatic NET makes a hormone**: most are non-functioning and present with mass effect or liver metastases, so a normal hormone panel does not exclude one.

## Test yourself

Think of the answer, then tap the question to see it.

## A 50-year-old has large-volume watery diarrhoea that persists during a fast, low potassium and a mass in the pancreatic tail. Which hormone should be measured?

Vasoactive intestinal peptide (VIP): a VIPoma causes secretory diarrhoea that continues while fasting, with low potassium and low gastric acid.

## A woman has recurrent jejunal ulcers and diarrhoea; fasting gastrin is high with a gastric pH of 1.5. What is the diagnosis, and what else should be checked?

Gastrinoma (Zollinger–Ellison syndrome); check calcium, PTH and prolactin, because about a quarter of gastrinomas are part of MEN1.

## A liver biopsy shows a well-differentiated NET with a Ki-67 index of 8%. What grade is it, and which scan shows where else it is?

Grade 2 (Ki-67 3–20%); somatostatin-receptor PET/CT stages it and shows whether receptor-targeted treatment could work.

## Why can octreotide worsen hypoglycaemia in a patient with an insulinoma?

It suppresses glucagon and growth hormone, which defend against low glucose, while many insulinomas have too few somatostatin receptors for insulin itself to fall.

[Add to my cards (4)](https://durgical.app/estudiar/?add=/en/endocrinology/neuroendocrine-tumours-markers-grading-and-functional-imaging/)

## Elsewhere in DurgiPedia

- [Pancreatic neuroendocrine tumours](https://durgical.com/en/general-pathology/pancreatic-neuroendocrine-tumours/)
- [Gastrointestinal neuroendocrine (carcinoid) tumours](https://durgical.com/en/general-pathology/gastrointestinal-neuroendocrine-tumours/)
- [Pulmonary neuroendocrine tumours](https://durgical.com/en/general-pathology/pulmonary-neuroendocrine-tumours/)
- [Multiple endocrine neoplasia (MEN) syndromes](https://durgical.com/en/general-pathology/multiple-endocrine-neoplasia-syndromes/)
- [Islets of Langerhans: α, β, δ cells](https://durgical.com/en/histology/islets-of-langerhans-cells/)

## Connections

## See it in 3D 4

The structures of Durgical's 3D anatomy where it is found.

- [Pancreas](https://durgical.com/en/anatomy/pancreas/)
- [Duodenum](https://durgical.com/en/anatomy/duodenum/)
- [Ileum](https://durgical.com/en/anatomy/ileum/)
- [Liver](https://durgical.com/en/anatomy/liver/)

## Related 5

- [When to think of an inherited endocrine syndrome: MEN1, MEN2 and their relatives](https://durgical.com/en/endocrinology/when-to-think-of-an-inherited-endocrine-syndrome-men1-men2-and-their-relatives/)
- [Hypoglycaemia: the Whipple triad, insulin and C-peptide](https://durgical.com/en/endocrinology/hypoglycaemia-the-whipple-triad-insulin-and-c-peptide/)
- [Carcinoid syndrome: flushing, diarrhoea and 5-HIAA](https://durgical.com/en/endocrinology/carcinoid-syndrome-flushing-diarrhoea-and-5-hiaa/)
- [Endocrine paraneoplastic syndromes](https://durgical.com/en/endocrinology/endocrine-paraneoplastic-syndromes/)
- [Cushing syndrome: confirm first, then locate](https://durgical.com/en/endocrinology/cushing-syndrome-confirm-first-then-locate/)

## Related conditions 6

- [Pancreatic neuroendocrine tumours (VIPoma, glucagonoma, somatostatinoma, non-functioning)](https://durgical.com/en/conditions/pancreatic-neuroendocrine-tumours/)
- [Insulinoma](https://durgical.com/en/conditions/insulinoma/)
- [Carcinoid syndrome](https://durgical.com/en/conditions/carcinoid-syndrome/)
- [Multiple endocrine neoplasia (MEN 1, 2A, 2B)](https://durgical.com/en/conditions/multiple-endocrine-neoplasia/)
- [Zollinger-Ellison syndrome (gastrinoma)](https://durgical.com/en/conditions/zollinger-ellison-syndrome/)
- [Hypoglycaemia (including insulin-induced)](https://durgical.com/en/conditions/hypoglycaemia/)

## In Pharmacology 2

- [Somatostatin analogues](https://durgical.com/en/pharmacology/classes/somatostatin-analogues/)
- [Octreotide](https://durgical.com/en/pharmacology/octreotide/)

[← All of endocrinology](https://durgical.com/en/endocrinology/)

Educational content; it does not replace a medical assessment and is not a clinical instruction. For confusion, persistent vomiting with diabetes, fainting or very low blood pressure in someone who takes or has stopped glucocorticoids, go to an emergency department at once.

Sources: [Pancreatic Neuroendocrine Tumors](https://www.ncbi.nlm.nih.gov/books/NBK448121/) (StatPearls (NCBI Bookshelf), 2025); [Gastrointestinal Neuroendocrine Tumors](https://www.ncbi.nlm.nih.gov/books/NBK448101/) (StatPearls (NCBI Bookshelf), 2025); [Insulinoma](https://www.ncbi.nlm.nih.gov/books/NBK544299/) (StatPearls (NCBI Bookshelf), 2025); [Gastrinoma](https://www.ncbi.nlm.nih.gov/books/NBK441842/) (StatPearls (NCBI Bookshelf), 2025); [VIPoma](https://www.ncbi.nlm.nih.gov/books/NBK507698/) (StatPearls (NCBI Bookshelf), 2025); [Glucagonoma](https://www.ncbi.nlm.nih.gov/books/NBK519500/) (StatPearls (NCBI Bookshelf), 2025); [Somatostatinoma](https://www.ncbi.nlm.nih.gov/books/NBK551613/) (StatPearls (NCBI Bookshelf), 2025).

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/endocrinology/neuroendocrine-tumours-markers-grading-and-functional-imaging/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/endocrinology/neuroendocrine-tumours-markers-grading-and-functional-imaging/
